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Abstract:
Introduction:
This  post-hoc  analysis  explored  Methotrexate  (MTX)  withdrawal  on  clinical,  radiographic,  and  functional  outcomes  in  patients  with  early
rheumatoid arthritis who previously received 52 weeks of Etanercept (ETN) + MTX treatment in the COMET study.
Methods:
Response at week 104 was analyzed based on the attainment of remission (28-joint disease activity score [DAS28] <2.6; Boolean); low disease
activity  (LDA;  2.6  ≤DAS28  ≤3.2);  normal  Health  Assessment  Questionnaire-Disability  Index  (HAQ-DI)  score  (≤0.5);  or  radiographic  non-
progression (change in modified Total Sharp Score ≤0.5).
Results:
Of 208 patients with baseline DAS28 scores at week 52, 105 received ETN + MTX and 103 received ETN over weeks 52-104 (Period 2). At week
104, rates of LDA (70% vs 67%), remission (59% vs 52%), and normal HAQ-DI (63% vs 61%) were similar in both arms; week 52 responders also
had a higher response rate at week 104 irrespective of treatment during Period 2. Overall rates of radiographic non-progression were higher for
ETN + MTX (90%) vs ETN (74%) at week 104; week 52 non-responders in the Period 2 ETN + MTX arm had a 21-27% higher rate vs ETN,
while the treatment difference was 11-12% for week 52 responders.
Conclusion:
The data suggest that for responders to ETN + MTX at week 52, MTX may be safely withdrawn. For non-responders where de-escalation would
not  be  considered,  the  continuation  of  the  combination  is  advisable.  Radiological  outcome was  numerically  worse,  but  of  uncertain  clinical
significance.
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1. INTRODUCTION
Etanercept  (ETN)  is  a  fully  human,  soluble  recombinant
Tumor Necrosis Factor (TNF) receptor fusion protein indicated
as monotherapy or in combination with methotrexate (MTX)
for  moderate-to-severe  Rheumatoid  Arthritis  (RA)  [1].  In
clinical  trials,  treatment  with  ETN  plus  MTX  nearly  halts
* Address correspondence to this author at Immunology & Inflammation Medical
Affairs,  Pfizer  Innovative  Health,  Pfizer  Japan  Inc,  3-22-7  Yoyogi  Shibuya-
ku,,Tokyo, Japan; E-mail: tomohiro.hirose@pfizer.com
structural  progression  and  produces  clinically  relevant
responses in patients with RA [2, 3]. For patients treated with
ETN  or  other  biological  Disease-modifying  Antirheumatic
Drugs  (bDMARDs)  in  combination  with  MTX,  European
League  Against  Rheuma-  tism  (EULAR)  and  American
College of Rheumatology (ACR) treatment guidelines advise
de-escalation  of  therapy  once  the  treatment  target  (e.g.  Low
Disease Activity [LDA] or remission) has been achieved [4, 5].
Most  de-escalation  studies  have  investigated  tapering  of  the
bDMARD  component  of  therapy  [6].  The  Combination  of
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Methotrexate  and  Etanercept  in  Early  Rheumatoid  Arthritis
(COMET)  trial  was  the  first  randomized  controlled  study  to
assess  withdrawal  of  MTX  from  bDMARD  combination
therapy  [7,  8].  This  is  a  clinically  relevant  question,  as  side
effects are commonly reported with MTX treatment [9].
The  COMET  trial  compared  remission  rates  and  radio-
graphic  progression  with  MTX  monotherapy  or  ETN  plus
MTX  in  patients  with  early,  moderate-to-severe  RA  [7].
Following  treatment  with  ETN  plus  MTX,  50%  of  patients
achieved clinical remission (based on 28-joint disease activity
score (DAS28))  at  52 weeks and 80% achieved radiographic
non-progression [7].
The objective of this post-hoc analysis was to explore the
effect of 52 weeks of MTX withdrawal on clinical remission
and radiographic non-progression in patients with RA who had
previously  received  ETN plus  MTX in  the  first  52  weeks  of
COMET.
2. METHODS
2.1. Study Design and Patient Selection
COMET is a 24-month, double-blind, randomized, parall-
el-group,  multicenter  study  in  outpatients  aged  18  years  or
older with adult-onset, moderate-to-severe RA. Details of the
study have been described previously [7].
Briefly, the study was conducted in two periods. In Period
1, participants were randomly assigned to receive ETN (50 mg/
week, administered as two separate subcutaneous injections of
25 mg each on the same day) plus oral MTX (starting dose 7.5
mg/week, titrated to a maximum of 20 mg/week over 8 weeks
in  patients  with  tender  or  swollen  joints),  or  oral  MTX  plus
placebo (administered as subcutaneous injections once a week)
for 52 weeks. Stable doses of oral corticosteroids (≤10 mg per
day  of  prednisone  or  an  equivalent  agent)  or  a  single  non-
steroidal  anti-inflammatory  drug  were  permitted  if  they  had
been started at least 4 weeks before baseline and kept constant
throughout the first 24 weeks of the study.
In Period 2 (weeks 52-104), patients were randomized to
either  continue  with  the  assigned  Period  1  treatment,  have
MTX  withdrawn  (for  those  receiving  ETN  +  MTX  during
Period  1),  or  have  ETN  added  (for  those  receiving  MTX  +
placebo during Period 1) (Fig. 1). Randomization for Period 1
and Period 2 treatments was performed at the start of the study,
with no re-randomization occurring at the end of Period 1.
This  post-hoc  analysis  focused  only  on  patients  who
received ETN + MTX in Period 1, and either continued with
combination therapy (ETN + MTX then ETN + MTX) or had
MTX withdrawn (ETN + MTX then ETN) in Period 2 (Fig. 1).
2.2. Study Outcomes and Data Analysis
The  response  to  therapy  at  the  end  of  week  104  was
analyzed  based  on  the  attainment  of  either:  (1)  LDA  (2.6
≤DAS28  ≤3.2);  (2)  remission  (DAS28  <2.6);  (3)  Normal
Health Assessment Questionnaire-Disability Index (HAQ-DI)
score  (≤0.5);  or  (4)  Radiographic  non-progression  (change
from  baseline  to  week  104  in  modified  Total  Sharp  Score
(mTSS) of ≤0.5).
Patients were stratified based on their clinical response at
the end of Period 1 (week 52) into (1) those who achieved or
did  not  achieve DAS28 LDA and (2)  those who achieved or
did not achieve remission. Demographic and baseline disease
characteristics  were  analyzed  according  to  week  52  DAS28
categories  (remission,  LDA  (excluding  remission),  non-
response). Continuous characteristics were analyzed using an
ordered  logistic  regression  model  of  week  52  DAS28
categories with baseline parameter as a predictor. Categorical
characteristics  were  analyzed  using  the  Cochran-Mantel-
Haenszel  test  of  linear  association.  This  was  performed  for
pooled treatment arms.
Odds Ratios (ORs) of achieving selected outcomes at week
104 for patients treated with continued ETN + MTX treatment
versus those who had MTX withdrawn were calculated using
logistic  regression  models  with  treatment,  week  52  DAS28
status, and their interaction as predictors of week 104 selected
outcomes.  For  each  week  52  DAS28  stratum,  response  rates
were  calculated  for  each  week  104  outcome,  according  to
treatment  arm.
3. RESULTS
Of  274  patients  who  received  ETN  +  MTX  in  Period  1,
208 patients had known baseline DAS28 scores at the start of
Period  2  (week  52);  for  DAS28  at  week  52,  56%  (117/208)
were in remission, 13% (27/208) had LDA, and 31% (64/208)
were non-responders. Non-responders were more likely to be
female,  have higher  Period 1  baseline  DAS28,  painful  joints
count,  fatigue,  HAQ-DI  score  and  Clinical  Disease  Activity
Index  (CDAI),  and  higher  mTSS  compared  with  patients  in
remission (Table S1).
Of the 208 patients with known baseline DAS28 scores at
week  52,  105  received  ETN  +  MTX  and  103  received  ETN
during Period 2. Patterns in patient demographics and Period 2
baseline  (i.e.  week  52)  disease  characteristics  across  the
DAS28  response  categories  were  broadly  similar  for  those
receiving ETN + MTX and those receiving ETN in Period 2
(Table 1). Patients who were in remission at week 52 had fewer
painful joints and lower DAS28, fatigue, HAQ-DI, and CDAI
scores  at  Period  2  baseline  (i.e.  week  52)  than  patients  who
were week 52 non-responders.  In contrast,  being female was
associated with LDA and non-responder status at week 52 in
those who went on to receive ETN + MTX in Period 2, but not
in those who went on to receive ETN (Table 1).
At  week  104,  overall  rates  of  DAS28  LDA  (70%  vs
67.0%), DAS28 remission (59% vs 52%), and normal HAQ-DI
(63% vs 61%) were similar in patients receiving ETN + MTX
versus  ETN  during  Period  2  (Fig.  2A  -  C).  Rates  of  radio-
graphic non-progression were higher in patients receiving ETN
+ MTX (90%) versus ETN (74%) during Period 2 (Fig. 2D).
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Table 1. Demographics and Period 2 baseline (i.e. week 52) disease characteristics by week 52 DAS28 response categories and
by Period 2 treatment arm.











Age [median], years (range) 54.3 (24.1–79.3) 64.5 (29.4–82.8) 51.9 (23.7–70.7) 55.4 (19.1–72.7) 60.4 (31.7–70.9) 56.0 (19.8–79.2)
Female, n (%) 28 (52) 14 (93) 33 (92) 45 (71) 8 (67) 24 (86)
Disease duration [median],
months (range)
6.0 (3.0–24.0) 6.0 (3.0–24.0) 7.0 (3.0–24.0) 8.0 (3.0–24.0) 7.0 (3.0–12.0) 10.0 (3.0–22.0)
DAS28 [median] (interquartile
range)
1.8 (1.3–2.1) 3.0 (2.8–3.1) 3.9 (3.5–4.1) 1.9 (1.6–2.2) 2.9 (2.8–3.0) 4.0 (3.6–4.7)
Painful joints–28 joint count
[median] (interquartile range)
0.0 (0.0–0.0) 1.0 (0.0–2.0) 2.0 (1.0–6.0) 0.0 (0.0–0.0) 1.0 (1.0–2.5) 3.0 (2.0–6.5)
Fatigue [median] (interquartile
range)
12.0 (3.0–31.0) 35.0 (12.0–51.0) 49.0 (25.0–66.0) 12.0 (3.0–26.0) 25.0 (5.0–52.5) 42.5 (21.5–60.0)
HAQ-DI, mean (SD) 0.4 (0.5) 0.9 (0.7) 0.9 (0.7) 0.2 (0.4) 0.7 (0.7) 1.2 (0.7)
CDAI, median (interquartile
range)
3.0 (2.0–4.0) 7.0 (6.0–9.0) 14.5 (8.0–17.0) 2.0 (1.0–5.0) 6.0 (5.0–10.5) 11.0 (8.5–18.5)
mTSS, median (interquartile
range)
2.0 (0.5–5.0) 6.3 (3.5–21.0) 2.0 (1.0–4.5) 3.0 (0.5–10.0) 3.8 (1.5–23.0) 6.0 (0.5–9.5)
CDAI, Clinical Disease Activity Index; DAS28, 28-joint Disease Activity Score; ETN, Etanercept; HAQ-DI, Health Assessment Questionnaire-Disability Index; LDA,
Low Disease Activity; mTSS, modified Total Sharp Score; MTX, Methotrexate; SD, Standard Deviation.
Fig. (1). Study design.
ETN, etanercept; MTX, methotrexate.
Rates and ORs of achieving DAS28 LDA, DAS28 remi-
ssion,  and  normal  HAQ-DI  at  week  104  were  two-  to  three-
times higher (non-significant) and 10 to 15 times higher odds
(significant) in week 52 responders (i.e. patients with DAS28
LDA or DAS28 remission at week 52) versus non-responders
both  in  the  ETN + MTX and  ETN arms.  The  non-responder
arm receiving ETN had the lowest rate of response (Figs. 2A -
C and Fig. 3). However, odds of achieving LDA, remission, or
normal  HAQ-DI  at  week  104,  though  higher  for  week  52
responders, were not significantly higher (i.e. ORs included 1)
for ETN + MTX versus ETN, irrespective of DAS28 status at
week 52 (Fig. 2).
Similar but more pronounced results  were seen for week
104  Boolean  remission  in  week  52  Boolean  remission  res-
ponders  versus  non-responders,  whereby  rates  for  week  104
Boolean remission were roughly four- to six-times higher for
week  52  remitters  versus  non-remitters  (Fig.  4).  In  patients
who had not achieved Boolean remission at week 52, 22% of
those receiving ETN + MTX in Period 2 went on to achieve
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receiving  ETN  alone.  In  patients  who  achieved  Boolean
remission at week 52, 78% of those receiving ETN + MTX in
Period 2 maintained Boolean remission to week 104 compared
with 71% of those receiving ETN alone.
Fig.  (2).  Odds ratios  (95% CI)  for  and proportions with achievement  of  (A)  DAS28 LDA, (B)  DAS28 remission,  (C)  normal  HAQ-DI,  or  (D)
radiographic non-progression at week 104 in patients receiving ETN + MTX or ETN during Period 2 (both ETN + MTX in Period 1) according to
DAS28 status at week 52.
CI, Confidence Interval; DAS28, 28-joint Disease Activity Score; ETN, Etanercept; HAQ-DI, Health Assessment Questionnaire-Disability Index;
LDA, Low Disease Activity; mTSS, modified Total Sharp Score; MTX, Methotrexate; OR, Odds Ratio. Bars indicate upper and lower 95% CIs.
Difference (%) = difference between treatment arms at week 104. DAS28 LDA = DAS28 ≤3.2. DAS28 remission = DAS28 <2.6. Normal HAQ-DI =
HAQ ≤0.5. Non-progression in annualized mTSS = change from year 2 baseline mTSS ≤0.5.
DAS28 status at
week 52 
Patients achieving DAS28 LDA
at week 104




DAS28 LDA 87 (60/69) 81 (61/75) 6
DAS28 non-LDA 36 (13/36) 29 (8/28) 7
DAS28 remission 93 (50/54) 86 (54/63) 7
DAS28 non-remission 45 (23/51) 38 (15/40) 7
Any 70 (73/105) 67 (69/103)
DAS28 status at
week 52 
DAS28 LDA 77 (53/69) 68 (51/75) 11
DAS28 non-LDA 25 (9/36) 11 (3/28) 14
DAS28 remission 85 (46/54) 70 (44/63) 15
DAS28 non-remission 31 (16/51) 25 (10/40) 6











Patients achieving DAS28 remission
at week 104








DAS28 LDA 77 (53/69) 75 (56/75) 2
DAS28 non-LDA 36 (13/36) 25 (7/28) 11
DAS28 remission 82 (44/54) 78 (49/63) 4
DAS28 non-remission 43 (22/51) 35 (14/40) 8
Any 63 (66/105) 61 (63/103)
Patients achieving normal HAQ-DI
at week 104








DAS28 LDA 89 (56/63) 78 (54/69) 11
DAS28 non-LDA 91 (30/33) 64 (16/25) 27
DAS28 remission 92 (45/49) 80 (47/59) 12
DAS28 non-remission 87 (41/47) 66 (23/35) 21
Any 90 (86/96) 74 (70/94)
Patients achieving non-progression
at week 104
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Fig. (3). Odds ratios (95% CI) for and proportions with achievement of DAS28 LDA or radiographic non-progression at week 104 by DAS28 status
at week 52 according to treatment group during Period 2.
CI, Confidence Interval; DAS28, 28-joint Disease Activity Score; ETN, Etanercept; mTSS, modified Total Sharp Score; MTX, Methotrexate. Bars
indicate upper and lower 95% CIs. Difference (%) = difference between treatment week 52 response/non-response groups in achieving radiographic





ETN + MTX/ETN + MTX ETN + MTX/ETN





A  DAS28 LDA





ETN + MTX/ETN + MTX 87 (60/69) 36 (13/36) 51
ETN + MTX/ETN 81 (61/75) 29 (8/28) 52
Difference
(%)





ETN + MTX/ETN + MTX 93 (50/54) 45 (23/51) 48
ETN + MTX/ETN 86 (54/63) 38 (15/40) 48
Difference
(%)





ETN + MTX/ETN + MTX 89 (56/63) 91 (30/33) –2
ETN + MTX/ETN 78 (54/69) 64 (16/25) 14
Difference
(%)





ETN + MTX/ETN + MTX 92 (45/49) 87 (41/47) 5






C  Non-progression in annualized mTSS
0 1 2 3 4 5 6 7 8
1510510 20 25 30 35 40 45 50 55
Week 104




1 2 3 4 5 6 7 80







36   The Open Rheumatology Journal, 2021, Volume 15 Emery et al.
Fig. (4). Odds ratios (95% CI) for and proportions with achievement of Boolean remission at week 104 in patients receiving ETN + MTX or ETN
during Period 2 (both ETN + MTX in Period 1).
CI, Confidence Interval; ETN, Etanercept; MTX, Methotrexate; OR, Odds Ratio. Bars indicate upper and lower 95% CIs. Difference (%) = difference
between treatment arms at week 104. Only patients with baseline and post-baseline values included for on-therapy visits. The OR compares ETN +
MTX/ETN + MTX vs ETN + MTX/ETN, obtained from logistic regression models with treatment, week 52 Boolean remission status, and their
interaction as predictors. Models are generated separately for each timepoint.
Rates of achieving radiographic non-progression at week
104  in  the  ETN  arm  were  higher  in  week  52  responders
(78-80%)  versus  non-responders  (64-66%)  (Fig.  2D).  How-
ever, in the ETN + MTX arm, rates of achieving radiographic
non-progression at week 104 were similarly high in week 52
responders (89-92%) and non-responders (87-91%) (Fig. 2D).
Patients  who were non-responders at  week 52 had a 21-27%
higher  rate  (3.6  to  5.6  times  higher  odds)  of  achieving
radiographic  non-progression  at  week  104  if  they  received
ETN  +  MTX  versus  ETN  alone  in  Period  2;  this  difference
between treatment arms was 11-12% (OR = 2.2 to 2.9) in those
who were week 52 responders (Fig. 2D).
4. DISCUSSION
The  COMET  trial  reported  improvements  in  clinical
remission and radiographic non-progression with ETN + MTX
at 1 year in patients with early, moderate-to-severe RA [7]. In
this post-hoc analysis, to our knowledge the first randomized
study of MTX withdrawal from bDMARD combination thera-
py, we observed higher rates of response (based on LDA and
remission) at 2 years in those patients who were responders to
ETN  +  MTX  at  1  year  compared  with  non-responders.  This
finding  was  irrespective  of  whether  patients  continued  to
receive ETN + MTX or were de-escalated to ETN during the
second  year.  In  patients  who  were  responders  at  week  52,
subsequent discontinuation of MTX for 52 weeks resulted in
minimal loss of clinical (based on DAS28 LDA and remission),
functional  (based  on  HAQ-DI),  and  radiological  (based  on
mTSS)  efficacy  compared  with  continuing  on  ETN +  MTX.
Treatment  with MTX is  associated with a  number  of  serious
side effects, including infections, hematologic effects, lympho-
proliferative disorders, nephrotoxicity, and hepatotoxicity, and
20-30% of patients with RA discontinue MTX within their first
year of therapy as a result [10 - 14]. Discontinuation of MTX
after  achieving  LDA  or  remission  may  benefit  patients  by
reducing the potential for adverse events, especially in elderly
patients who may have renal or hepatic dysfunction or may be
more susceptible to dosage errors. This approach also follows
EULAR and ACR guidelines for patients with RA treated with
DMARDs  in  combination  with  MTX,  which  advise  de-
escalation  of  therapy  once  the  treatment  target  has  been
achieved  [4,  5],  thus  providing  new  evidence  to  support
guidelines for MTX tapering. Although the concomitant use of
MTX can  also  help  to  reduce  immunogenicity  seen  with  the
use  of  biologics  [15,  16],  ETN  has  a  low  immunogenicity
profile  [17],  meaning  patients  do  not  require  this  added
suppression  of  immunogenicity  afforded  by  MTX.
In patients who did not achieve LDA or remission after 1
year of ETN + MTX, we observed significantly greater odds of
achieving  radiographic  non-progression  if  patients  continued
on ETN + MTX rather than having MTX withdrawn. For these
patients,  our  findings  support  continuation  of  combination
therapy  and  withdrawal  of  MTX  as  soon  as  remission  is
achieved.  The  findings  have  clear  implications  for  manage-
ment;  responders  can  taper  MTX  successfully  while  non-
responders need to continue the combination to maintain their
level of response.
This study has a number of limitations.  This was a post-
hoc  analysis  of  COMET,  and  the  original  study  was  not
powered to allow firm conclusions to be drawn on the impact
of  withdrawing  MTX  based  on  week-52  DAS28  response
status.  Furthermore,  while  MTX withdrawal  was considered,
there  was  no  assessment  of  the  number  of  patients  who
received  MTX  dose  reductions  during  the  study.
CONCLUSION
Notwithstanding  these  limitations,  this  post-hoc  analysis
may help to guide the management of RA. For responders to
the combination ETN + MTX (especially those in remission),
the data suggest that MTX can be safely withdrawn. For those
not achieving LDA, in whom de-escalation would not normally
be  considered,  the  data  indicate  that  continuation  of  the
combination  is  advisable.
Week 52 Boolean
remission strata 
Patients achieving Boolean remission at week 104




Boolean remission 78 (18/23) 71 (20/28) 7
Boolean non-remission 22 (17/79) 11 (8/72) 11
Difference
(%)
Boolean remission Boolean non-remission
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LIST OF ABBREVIATIONS
CDAI = Clinical Disease Activity Index
DAS28 = 28-joint Disease Activity Score
dMARD = disease-Modifying Antirheumatic Drug
ETN = Etanercept
HAQ-DI = Health Assessment Questionnaire-Disability Index
LDA = Low Disease Activity
mTSS = modified Total Sharp Score
MTX = Methotrexate
OR = Odds Ratio
RA = Rheumatoid Arthritis
TNF = Tumor Necrosis Factor
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